Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

Cytokine Storm Biomarker Quantitation for COVID-19 Research Applications

Products are for professional/laboratory use only.  In response to SARS-CoV-2 viral infection of the lungs, a cytokine storm can result. Over-produced immune cells and their signaling molecules cause a local inflammatory response in the lungs leading to respiratory distress and reduced blood oxygen levels. A cytokine storm can contribute to severe clinical symptoms and poor patient outcomes.

Some early publications on the cytokine profile for COVID-19 have found increased levels of IL- 2, IL-7, G-CSF, IP-10, MCP-1, MIP-1α, TNFα, and Ferritin.1 In a separate study, IL-6 was also found to increase with SARS-CoV-2 infection.2

IL-1β, IL- 1RA, IL-8, IL-9, IL-10, FGF-basic, GM-CSF, IFNγ, MIP-1β, PDGF, and VEGF have also been shown to be increased in COVID-19 patients compared to healthy subjects.3

MILLIPLEX® multiplex immunoassays offer researchers the ability to simultaneously quantitate a large number of analytes critical to understanding the immune response in humans. The 48-plex Human Cytokine/Chemokine/Growth Factor Panel A saves time and sample volume for a snapshot of analyte profiles during a cytokine storm, sepsis, or other disease states.


Find out more

Download Flyer >

WEBINAR RECORDING

Use of a 48-plex quantitative immune panel to profile three different diseases
Quantitative analysis of 48 analytes with MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A

 

 

 

 

 

 

 

 

 

 

f


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


References

  1. Mehta, P., et al. 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet Published Online March 12, 2020 https://doi.org/10.1016/S0140-6736(20)30630-9
  2. Ruan, Q., et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med (2020). https://doi.org/10.1007/s00134-020- 05991-x
  3. Huang, C., et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Published Online January 24, 2020 https://doi.org/10.1016/S0140-6736(20)30183-5

 


See the latest list of available analytes

Download Merck Analyte Update >

Request a Quote

Click Here >



Request a Quote

Request Quote

Recent Posts

2027 Abacus dx Emerging Investigators Grant

COMING SOON Grant in Research Funding Empowering the Next Generation of Scientific Leaders Stay tuned for the 2027 Abacus dx Emerging Investigators Grant. More information…

Read full article

Developing Diagnostic Kits for Ovarian Cancer

In Australia, ovarian cancer is the deadliest reproductive cancer. The average five‑year survival rate sits at around 49%, compared with about 92% for breast cancer,…

Read full article

Merck FemtoQuest™

Gain your desired immunoassay sensitivity with the ultrasensitive FemtoQuest™ system Measure down to femtogram/mL levels Improved precision and robust data Perform dual-plex and single analyte…

Read full article